Robert H Goertsches

Summary

Affiliation: University of Rostock
Country: Germany

Publications

  1. doi request reprint Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks
    Robert H Goertsches
    Department of Neurology, University of Rostock, Gehlsheimer Strasse 20, 18147 Rostock, Germany
    J Neurol 255:48-57. 2008
  2. doi request reprint Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS
    Robert H Goertsches
    Department of Neurology, University of Rostock, Gehlsheimer Str 20, 18047 Rostock, Germany
    Pharmacogenomics 11:147-61. 2010
  3. pmc Integrative modeling of transcriptional regulation in response to antirheumatic therapy
    Michael Hecker
    Leibniz Institute for Natural Product Research and Infection Biology Hans Knoell Institute, Jena, Germany
    BMC Bioinformatics 10:262. 2009
  4. doi request reprint Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy
    Robert H Goertsches
    University of Rostock, Department of Neurology, Gehlsheimer Strasse 20, 18147 Rostock, Germany
    Pharmacogenomics 12:423-32. 2011
  5. doi request reprint Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, 08035 Barcelona, Spain
    Mult Scler 14:412-4. 2008
  6. ncbi request reprint MS therapy research applying genome-wide RNA profiling of peripheral blood
    R Goertsches
    Department of Immunology, Clinic of Neurology, University of Rostock, Schillingallee 70, D 18057 Rostock, Germany
    Int MS J 14:98-107. 2007
  7. ncbi request reprint Detection of apoptotic cells in cerebrospinal fluid of patients suffering from neurological disease
    R Goertsches
    Institute of Immunology, University of Rostock, Rostock, Germany
    J Neuroimmunol 188:175-80. 2007
  8. ncbi request reprint Multiple sclerosis therapy monitoring based on gene expression
    Robert Goertsches
    Department of Immunology, University of Rostock, Schillingallee 70, D 18055 Rostock, Germany
    Curr Pharm Des 12:3761-79. 2006
  9. ncbi request reprint Immunoglobulins--basic considerations
    Eilhard Mix
    University of Rostock, Dept of Neurology, Gehlsheimer Str 20, 18147, Rostock, Germany
    J Neurol 253:V9-17. 2006
  10. ncbi request reprint Plasma osteopontin levels in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escola d Infermeria 2a planta, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 158:231-9. 2005

Collaborators

Detail Information

Publications18

  1. doi request reprint Monitoring of multiple sclerosis immunotherapy: from single candidates to biomarker networks
    Robert H Goertsches
    Department of Neurology, University of Rostock, Gehlsheimer Strasse 20, 18147 Rostock, Germany
    J Neurol 255:48-57. 2008
    ....
  2. doi request reprint Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS
    Robert H Goertsches
    Department of Neurology, University of Rostock, Gehlsheimer Str 20, 18047 Rostock, Germany
    Pharmacogenomics 11:147-61. 2010
    ..In multiple sclerosis patients, treatment with recombinant IFN-beta (rIFN-beta) is partially efficient in reducing clinical exacerbations. However, its molecular mechanism of action is still under scrutiny...
  3. pmc Integrative modeling of transcriptional regulation in response to antirheumatic therapy
    Michael Hecker
    Leibniz Institute for Natural Product Research and Infection Biology Hans Knoell Institute, Jena, Germany
    BMC Bioinformatics 10:262. 2009
    ..Etanercept is known to reduce disease symptoms and progression in RA, but the underlying molecular mechanisms have not been fully elucidated...
  4. doi request reprint Sieving treatment biomarkers from blood gene-expression profiles: a pharmacogenomic update on two types of multiple sclerosis therapy
    Robert H Goertsches
    University of Rostock, Department of Neurology, Gehlsheimer Strasse 20, 18147 Rostock, Germany
    Pharmacogenomics 12:423-32. 2011
    ..We will discuss recurrently reported biomarker candidates, emphasizing those of immunologically meaning, and review studies with network module outputs...
  5. doi request reprint Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, 08035 Barcelona, Spain
    Mult Scler 14:412-4. 2008
    ..Transcript expression in brain lesions from MS patients was increased. These findings suggest C10orf27 as a candidate gene for MS susceptibility and pathogenesis...
  6. ncbi request reprint MS therapy research applying genome-wide RNA profiling of peripheral blood
    R Goertsches
    Department of Immunology, Clinic of Neurology, University of Rostock, Schillingallee 70, D 18057 Rostock, Germany
    Int MS J 14:98-107. 2007
    ..This work reviews the state of the art in MS therapy research applying genomewide screening methods at the transcriptome level in peripheral blood cells of humans...
  7. ncbi request reprint Detection of apoptotic cells in cerebrospinal fluid of patients suffering from neurological disease
    R Goertsches
    Institute of Immunology, University of Rostock, Rostock, Germany
    J Neuroimmunol 188:175-80. 2007
    ..In contrast, expression of the anti-apoptotic protein Bcl-2 did not differ between investigated patient groups...
  8. ncbi request reprint Multiple sclerosis therapy monitoring based on gene expression
    Robert Goertsches
    Department of Immunology, University of Rostock, Schillingallee 70, D 18055 Rostock, Germany
    Curr Pharm Des 12:3761-79. 2006
    ..It discusses implications in understanding disease pathogenicity, diagnostic markers, the identification of new therapeutic targets and a classification of patients towards the advent of tailored therapies...
  9. ncbi request reprint Immunoglobulins--basic considerations
    Eilhard Mix
    University of Rostock, Dept of Neurology, Gehlsheimer Str 20, 18147, Rostock, Germany
    J Neurol 253:V9-17. 2006
    ..The generation of genetically engineered monoclonal Abs (mAbs) has revolutionized the diagnostic and therapeutic potential of Abs in almost all disciplines of modern medicine...
  10. ncbi request reprint Plasma osteopontin levels in multiple sclerosis
    Manuel Comabella
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escola d Infermeria 2a planta, Pg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 158:231-9. 2005
    ....
  11. pmc mtDNA nt13708A variant increases the risk of multiple sclerosis
    Xinhua Yu
    Section of Immunogenetics, University of Rostock, Rostock, Germany
    PLoS ONE 3:e1530. 2008
    ..Mitochondrial DNA (mtDNA) polymorphism is a possible factor contributing to the maternal parent-of-origin effect in multiple sclerosis (MS) susceptibility...
  12. ncbi request reprint Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis
    Robert Goertsches
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron HUVH, Escuela de Enfermeria 2 a planta, Psg Vall d Hebron 119 129, 08035 Barcelona, Spain
    J Neuroimmunol 164:140-7. 2005
    ..No association was detected between different genotypes and disease severity measured by the Multiple Sclerosis Severity Score (MSSS). These findings suggest a potentially important role for the ADAMTS14 gene in predisposition to MS...
  13. ncbi request reprint Comparative genomics for the investigation of autoimmune diseases
    Steffen Möller
    University of Rostock, Institutes of Immunology, Schillingallee 70, 18057 Rostock, Germany
    Curr Pharm Des 12:3707-22. 2006
    ....
  14. ncbi request reprint Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis
    Eva Julià
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Neuroimmunol 180:147-58. 2006
    ..To evaluate whether T cells expressing CCR5 and CXCR3 from multiple sclerosis (MS) patients are more resistant to apoptosis...
  15. ncbi request reprint Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy
    Martin Eggert
    Department of Internal Medicine, Rostock Clinic South, Südring 81, 18059 Rostock, Germany
    J Neurol Sci 264:145-50. 2008
    ..In summary, pulse therapy resulted in a decreased level of activated p65 NF-kappaB subunits leading to decreased levels of transcriptionally active pro-inflammatory NF-kappaB...
  16. ncbi request reprint Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans
    Tomas Marques-Bonet
    Departament de Ciencies Experimentals i de la Salut, Universitat Pompeu Fabra, Barcelona, Spain
    Bioinformatics 21:ii180-1. 2005
    ....
  17. ncbi request reprint Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans
    Maria Ban
    University of Cambridge, Department of Clinical Neurosciences, Addenbrooke s Hospital, Hills Road, Cambridge, UK
    J Neuroimmunol 179:108-16. 2006
    ..Association mapping across the candidate genes implicated by these markers in 937 UK trio families revealed modestly associated haplotypes in JAG1 (p=0.019) on chromosome 20p12.2 and POU2AF1 (p=0.003) on chromosome 11q23.1...
  18. ncbi request reprint A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease
    Robert Goertsches
    Neuroimmunology Unit, Hospital Vall d Hebron, Barcelona, Spain
    J Neuroimmunol 143:124-8. 2003
    ..Our results provide support for the presence of multiple coding regions that contain MS susceptibility genes of small or moderate effect...